RNA Therapeutics Market

Market Outlook

The global next generation RNA therapeutics market, is projected to reach USD 0.1 billion in 2029 and USD 2.7 billion by 2035, representing a CAGR of 63.1% during the forecast period 2029 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of modality, the therapeutics sub segment is expected to hold the highest share (more than 80%) of the market in 2035.
• Based on the type of molecule, saRNA sub segment is likely to occupy the largest share (approximately 60%) of the market in 2035.
• With respect to target indication, the advanced solid tumors sub segment will dominate the future market.
• Based on the route of administration, intratumoral sub segment is projected to capture the largest share (around 35%) of the market in 2035.
• In terms of geographical regions, North America will hold the highest market share by securing over 65% of the market share.

Market Introduction

Over the years, RNA based therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA therapeutics play a crucial role in protein production and regulation of gene functions. In addition, they offer enhanced therapeutic and safety profiles as compared to traditional treatment approaches. However, there are some concerns associated with the highly unstable nature of such molecules and their delivery in adequate concentrations.

To overcome the above-mentioned hurdles, global industry leaders are advancing the development of next-generation RNA therapeutics and vaccines. In fact, a number of these companies also offer advanced technology platforms, to design, develop and manufacture novel RNA therapeutics / vaccines.

Emerging modalities, including circular RNA (circRNA), endless RNA (eRNA), self-amplifying RNA (saRNA), and transfer RNA (tRNA), demonstrate enhanced structural stability, expression specificity, targeted delivery and non-immunogenic properties. These attributes enable their application across diverse therapeutic areas, such as influenza and breast cancer among others.

Considering the prevalent trends and projected opportunity associated with the overall RNA therapeutics and vaccines, we believe that the domain is likely to witness lucrative market growth in the foreseen future.

Market Segmentation

Based on the research, we have segmented the Next Generation RNA Therapeutics Market into type of modality, type of molecule, target indication, route of administration and geographical regions.

Next Generation RNA Therapeutics Market, by Type of Modality

• Therapeutics
• Vaccines

Next Generation RNA Therapeutics Market, by Type of Molecule

• circRNA
• sacRNA
• saRNA

Next Generation RNA Therapeutics Market, by Target Indication

• Advanced Solid Tumors
• Hepatocellular Carcinoma
• Inherited Bone Marrow Failure Syndrome
• Radiation-Induced Xerostomia and Hyposalivation
• Seasonal Influenza

Next Generation RNA Therapeutics Market, by Route of Administration

• Intraductal Route
• Intramuscular Route
• Intratumoral Route
• Intravenous Route

Next Generation RNA Therapeutics Market, by Geographical Regions

• North America
  • US
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • Singapore

Next Generation RNA Therapeutics Industry Key Insights

What Factors are Driving Increased Adoption of Next Generation RNA Therapeutics?

• Rising Focus on Personalized Medicine: The growing focus on treating diseases at a molecular level through targeted RNA-based interventions is a key driver for the next generation RNA therapeutics and vaccines market. It is important to note that advancements in messenger RNA mRNA vaccines & therapeutics market platforms, spurred by the success of COVID-19 vaccines, are enabling personalized RNA medicine for oncology, rare genetic disorders, and infectious diseases.
• Increasing Investments and Technological Advancements: Notably, academic institutions and biopharmaceutical companies are providing substantial funding for RNA related research. Additionally, breakthroughs in delivery systems, such as lipid nanoparticles (LNPs) and stability enhancements, are accelerating R&D and market expansion.

What Regulations Govern Next Generation RNA Therapeutics and Vaccines Availability and Accuracy?

• The US FDA Biologics License Application (BLA) Pathway: The US FDA regulates RNA therapeutics and vaccines as biologics under the Center for Biologics Evaluation and Research (CBER). Therefore, these therapies require premarket approval through pathways like BLA for vaccines or Investigational New Drug (IND) applications for therapeutics to ensure safety, efficacy, and quality.
• The European Union EMA Guidelines and ATMP Framework: It is worth highlighting that the European Medicines Agency (EMA) often classifies RNA therapeutics as Advanced Therapy Medicinal Products (ATMPs). This designation requires centralized marketing authorization of novel RNA therapeutics through the EMA. Further, these novel RNA therapeutics require post-market safety surveillance and comprehensive clinical validation in compliance with established guidelines.

Industry Experts on Next Generation RNA Therapeutics Industry

The market report includes transcripts of the following third-party discussions:

• Co-Founder, Small Company in the US
• Director of Strategic Partnerships, Large Company in Sweden
• Former Chief Scientific Officer, Mid-Sized Company in the US

In regard to evolving research in RNA field, Dr. Bijoyita Roy (RNA Research Senior Scientist at New England Biolabs), stated that, “the field of RNA biology, it's advancing at such an unbelievable pace. And with the success that we have seen with RNA-based therapeutics, you can only imagine how this modality will be adapted for other indications. We should definitely expect to see innovations on all fronts. If you look back, innovation in basic research over the past four decades or so has really enabled this technology to go where it is today. So, I firmly believe that there will be innovations in basic and applied research on all fronts, and we'll see really exciting developments.”

Market Share Insights

Which Modality Accounts for the Largest Share of RNA Therapeutics Market?

• The market for next generation RNA therapeutics is well distributed across various types of modalities, such as therapeutics and vaccines.
• In 2035, the therapeutics sub segment is likely to occupy a higher share (>80%), as per the next generation RNA therapeutics market forecast. Further, this sub segment is likely to witness a significant growth rate during the forecast period.
• This is primarily due to the broader application potential of therapeutics as compared to vaccines. Unlike vaccines, which are primarily preventive and target infectious diseases, therapeutics can address both chronic and acute diseases, expanding their market potential.

Which Target Indication Accounts for the Largest Share of RNA Therapeutics Market?

• The global market is broadly categorized across different target indications, such as advanced solid tumors, hepatocellular carcinoma, inherited bone marrow failure syndromes, radiation-induced xerostomia and hyposalivation and seasonal influenza.
• Based on the next generation RNA therapeutics market report, the advanced solid tumors sub segment is expected to occupy the highest (~35%) market share in 2035. This is due to the growing prevalence of oncological disorders across the globe, raising serious health concerns.
• The inherited bone marrow failure syndrome sub segment is likely to witness a higher CAGR in the coming future. This is owing to the fact that inherited bone marrow failure syndromes are rare and mostly monogenic disorders, for which conventional treatments are limited.

Which Route of Administration Segment Hold the Highest Share in the Future?

• The global market is further sub-segmented into intraductal, intramuscular, intratumoral and intravenous routes of administration.
• In 2035, intratumoral route sub segment is likely to occupy the highest market share (~35%), as per next generation next generation RNA therapeutics market analysis. This is owing to the fact that direct intratumoral drug administration enhances local retention within the tumor, thereby improving therapeutic efficacy while minimizing off-target toxicity.
• The intraductal route is expected to grow at a higher CAGR of 70.2% during the forecast period. This is due to the fact that intraductal administration using optimized nanocarriers increases tissue retention and localization in the mammary gland.

Next Generation RNA Therapeutics Market: Report Attributes

Frequently Asked Questions